Ramat Gan, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Odysight.ai® (NASDAQ/TASE: ODYS) today announced the receipt of a purchase order from Honeywell Aerospace APU Division for a proof-of-concept (PoC) collaboration to evaluate Odysight.ai’s visual sensing platform across Honeywell Aerospace Auxiliary Power Units (APU) portfolio.
Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS Insider
The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.
Ophthalmic Clinical Trials Market Size to Reach USD 3.30 Billion by 2035 as Gene Therapy and Retinal Disease Drug Development Accelerate – SNS Insider
The U.S. Ophthalmic Clinical Trials Market was valued at USD 0.66 Billion in 2025 and is projected to reach USD 1.25 Billion by 2035, while Europe is expected to grow from USD 0.49 Billion to USD 0.89 Billion during the forecast period, driven by expanding retinal disease pipelines and ophthalmic innovation.
Odysight.ai® Receives Purchase Order from Honeywell Aerospace APU Division to Launch Proof of Concept of Odysight.ai’s Advanced Predictive Maintenance Vision-Based Monitoring System on Honeywell Aerospace Auxiliary Power Units Portfolio
Ramat Gan, Israel, June 18, 2026 (GLOBE NEWSWIRE) — Odysight.ai® (NASDAQ/TASE: ODYS) today announced the receipt of a purchase order from Honeywell Aerospace APU Division for a proof-of-concept (PoC) collaboration to evaluate Odysight.ai’s visual sensing platform across Honeywell Aerospace Auxiliary Power Units (APU) portfolio.
AVI-SPL Launches Autonomous Freight Operations with Volvo Autonomous Solutions
Fort Worth, Texas, June 18, 2026 (GLOBE NEWSWIRE) — AVI-SPL, a leading global technology solutions provider, and Volvo Autonomous Solutions (V.A.S.) today announced that they have started commercial autonomous freight operations between Dallas and Houston using the Volvo VNL Autonomous powered by the Aurora Driver.
Triller Group Inc. Announces Share Consolidation
Los Angeles, June 18, 2026 (GLOBE NEWSWIRE) — Triller Group Inc. (Nasdaq: ILLR / ILLRW) (the “Company” or “Triller”) today announced that it will effect a share consolidation of its common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-10, effective on June 23, 2026 (the “Share Consolidation”). The Company’s Common Stock are expected to begin trading on a post-consolidation basis at the open of the market session on June 23, 2026. Upon the market opening on June 23, 2026, the Company’s Common Stock will continue to be traded on The Nasdaq Stock Market under the symbol “ILLR” with the new CUSIP number 895970309.
Preclinical Imaging Market Size to Reach USD 7.24 Billion by 2035 as Pharmaceutical R&D and Drug Discovery Investments Accelerate – SNS Insider
The U.S. Preclinical Imaging Market was valued at USD 1.12 Billion in 2025 and is projected to reach USD 1.85 Billion by 2035, while Europe is expected to grow from USD 1.28 Billion to USD 1.95 Billion, driven by expanding pharmaceutical research, imaging biomarker adoption, and advanced preclinical research infrastructure.
Quantum X Labs Launches Integrated Quantum Computing Program Combining Its Clinical Trials Data Analysis Quantum Algorithm and Its Quantum Error Correction Decoder
Strategic initiative to accelerate practical quantum computing through cross-platform execution to reach fault-tolerant performance optimization
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial results for the full fiscal year ended March 31, 2026.
Nightfood Holdings Inc. (OTCQB: NGTF) Builds AI-Driven Automation Tools for Hospitality, Pharmaceutical, Lab and Industrial Spaces
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) — via AINewsWire — Nightfood Holdings Inc. (OTCQB: NGTF) today announces its placement in an editorial published by AINewsWire (“AINW”), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
Richtech Robotics Launches Interactive Livestream Featuring AI-Powered Robot ADAM, Enabling Online Users to Engage with ADAM
Initiative is part of the next era of product engagement and the future of embodied AI using NVIDIA technology
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
Company to Loan $6.5 Million Prior to Closing to Fund Order Backlog and Working Capital Needs – Combined Company to be Renamed NOMAD Power Solutions, Inc. and Trade Under a New Ticker Symbol
SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
Company announces name change to SRX Global in conjunction with transaction closing
Company’s stock to remain trading on the NYSE American (“NYSE”) under ticker symbol “SRXH”
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
SARASOTA, FLA., June 18, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo’s common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development
Aether Holdings Officially Launches Alphid™, Expanding Its Agentic AI Platform with Brokerage Connectivity Across More Than 30 Brokerage Firms
New feature integrates research, market intelligence, and portfolio analysis through brokerage platforms connectivity, serving over 400 million investors
Meet Your Cosmic Crushes with New Refreshing Summer Drinks Available Today at Scooter’s Coffee®
Scooter's Coffee today launched limited-time flavors in collaboration with Little Debbie®, a new Bombshell lineup featuring strawberry and dragon fruit flavors, and a new trio of delicious Dirty Sodas.
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Broader pharmacy access, channel expansion, and payer coverage position Arbli™ for increased prescription volume and revenue growth